Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018

SAN DIEGO, Oct. 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, will hold a conference call to discuss financial results and business highlights for the quarter ended September 30, 2018, as follows:

The teleconference replay will be available approximately two hours after completion through Monday, November 12, 2018, at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The replay access code is 9158219.  The archived webcast will be available via the aforementioned URLs. 

About Evofem BiosciencesEvofem Biosciences, Inc., (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Evofem is leveraging its proprietary Multipurpose Vaginal pH Regulator (MVP-R) to develop product candidates for multiple indications, including contraception, the prevention of urogenital transmission of chlamydia and gonorrhea in women, and recurrent bacterial vaginosis. For more information regarding Evofem, please visit www.evofem.com.

Investor ContactAmy RaskopfEvofem Biosciences, Inc.[email protected]O: (858) 550-1900 x167M: (917) 673-5775

Media ContactSophia OnonyeRXMD[email protected]O: (646) 599-8630M: (917) 557-1909

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-third-quarter-2018-results-on-november-7-2018-300736687.html

SOURCE Evofem Biosciences, Inc.